{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:47Z","timestamp":1787977067511,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12978"],"award-info":[{"award-number":["12978"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008359","name":"Maag Lever Darm Stichting","doi-asserted-by":"publisher","award":["WO 22-17"],"award-info":[{"award-number":["WO 22-17"]}],"id":[{"id":"10.13039\/501100008359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-functioning pancreatic neuroendocrine tumors (NF-pNETs) show a variable prognosis. Despite 40\u201360% of patients remaining recurrence-free after surgery, guidelines recommend\u2009\u2265\u200910 years of follow-up. Recent studies identify prognostic subgroups based on ATRX, DAXX, and MEN1 mutations and chromosomal aneuploidy, highlighting a subgroup with favorable prognosis. We aimed to classify resected NF-pNETs into molecular subgroups using ATRX, DAXX, and Menin immunohistochemistry as surrogate markers for genomic status. To do so, we retrospectively collected resected primary sporadic grade 1 and 2 NF-pNETs without synchronous metastases from five international local pathology archives. ATRX, DAXX, and Menin immunohistochemistry was performed, and tumors were categorized into three groups: ATRX-DAXX-loss-group (ATRX or DAXX loss), isolated-Menin-loss-group (Menin loss without ATRX and DAXX loss), and unspecified-group (retained Menin, ATRX and DAXX). Kaplan-Meier analysis evaluated prognostic differences, and multivariable Cox regression assessed the added value of molecular subgroups beyond established prognostic factors. In total, 139 patients with grade 1 (64%) and 2 (36%) NF-pNETs were included. The median follow-up was 28 months (range 0\u2013195) and recurrences occurred in 20% (28\/139). No recurrences occurred in the isolated-Menin-loss-group (0\/33), versus 12.5% (8\/64) in the unspecified-group and 48% (20\/42) in the ATRX-DAXX-loss-group. Kaplan-Meier analysis showed better recurrence-free interval in the isolated-Menin-loss-group than other subgroups (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). In univariate analysis, the isolated-Menin-loss-group had a lower recurrence hazard (HR 0.03; 95%CI: 0.00\u20130.55;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.018), than other subgroups, with little change in the hazard ratio after adjustment, but loss of significance. In conclusion, molecular subclassification by immunohistochemistry identifies NF-pNET patients with a low risk of recurrence and lays the groundwork for future prospective studies assessing genetics-based risk stratification as a tool for guiding clinical management.\n                  <\/jats:p>","DOI":"10.1007\/s12022-026-09933-z","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:41:18Z","timestamp":1787974878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance"],"prefix":"10.1007","volume":"37","author":[{"given":"Anna Vera Ditte","family":"Verschuur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel Maximillian","family":"Hackeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvir","family":"Jairam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busra","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmijn Sterre","family":"Westendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno Reginaldus","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlof Dirk","family":"Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Teresa","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Michael","family":"Heaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Mo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Perren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen Marie Anton","family":"Dreijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Jacqueline Maria Nieveen","family":"van Dijkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza Fari\u00f1a","family":"Sarasqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatur Dilip","family":"Singhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd Geert","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewijk Adriaan Anton","family":"Brosens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"9933_CR1","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40618-022-01985-2","volume":"46","author":"X Liu","year":"2023","unstructured":"Liu X, Chen B, Chen J, Su Z, Sun S (2023) The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. J Endocrinol Invest 46:1373\u20131384. https:\/\/doi.org\/10.1007\/s40618-022-01985-2","journal-title":"J Endocrinol Invest"},{"key":"9933_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","volume":"27","author":"MB Sonbol","year":"2022","unstructured":"Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, Cleary SP, Hobday T, Halfdanarson TR (2022) Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist 27:573\u2013578. https:\/\/doi.org\/10.1093\/oncolo\/oyac049","journal-title":"Oncologist"},{"key":"9933_CR3","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed 1 Aug 2026"},{"key":"9933_CR4","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, Grande E, Kjaer A, Koumarianou A, de Mestier L, Partelli S, Perren A, St\u00e4ttner S, Valle JW, Fazio N (2023) European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 35:e13343. https:\/\/doi.org\/10.1111\/jne.13343","journal-title":"J Neuroendocrinol"},{"key":"9933_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Kl\u00f6ppel G, Reed N, Kianmanesh R, Jensen RT, Vienna Consensus Conference participants (2016) ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103:153\u2013171. https:\/\/doi.org\/10.1159\/000443171","journal-title":"Neuroendocrinology"},{"key":"9933_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","volume":"49","author":"TR Halfdanarson","year":"2020","unstructured":"Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O\u2019Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA (2020) The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 49:863\u2013881. https:\/\/doi.org\/10.1097\/MPA.0000000000001597","journal-title":"Pancreas"},{"key":"9933_CR7","doi-asserted-by":"publisher","first-page":"e1063-e1067","DOI":"10.1097\/SLA.0000000000005809","volume":"278","author":"A Pulvirenti","year":"2023","unstructured":"Pulvirenti A, Javed AA, Michelakos T, Sekigami Y, Zheng J, Kalvin HL, McIntyre CA, Nebbia M, Chou JF, Gonen M, Raj N, Reidy-Lagunes DL, Zureikat AH, Ferrone CR, He J, Wei AC, PAncreatic Neuroendocrine Disease Alliance (PANDA) (2023) Recurring Pancreatic Neuroendocrine Tumor: Timing and Pattern of Recurrence and Current Treatment. Ann Surg 278:e1063-e1067. https:\/\/doi.org\/10.1097\/SLA.0000000000005809","journal-title":"Ann Surg"},{"key":"9933_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY, O\u2019Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD (2022) Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut 71:961\u2013973. https:\/\/doi.org\/10.1136\/gutjnl-2020-322595","journal-title":"Gut"},{"key":"9933_CR9","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1245\/s10434-018-6518-2","volume":"25","author":"CG Gen\u00e7","year":"2018","unstructured":"Gen\u00e7 CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C, Kl\u00fcmpen HJ, van Eijck CHJ, Nieveen van Dijkum EJM (2018) Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol 25:2467\u20132474. https:\/\/doi.org\/10.1245\/s10434-018-6518-2","journal-title":"Ann Surg Oncol"},{"key":"9933_CR10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1097\/SLA.0000000000002123","volume":"267","author":"CG Gen\u00e7","year":"2018","unstructured":"Gen\u00e7 CG, Jilesen AP, Partelli S, Falconi M, Muffatti F, van Kemenade FJ, van Eeden S, Verheij J, van Dieren S, van Eijck CHJ, Nieveen van Dijkum EJM (2018) A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg 267:1148\u20131154. https:\/\/doi.org\/10.1097\/SLA.0000000000002123","journal-title":"Ann Surg"},{"key":"9933_CR11","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.3390\/cancers13092242","volume":"13","author":"CM Heidsma","year":"2021","unstructured":"Heidsma CM, Tsilimigras DI, Rocha F, Abbott DE, Fields R, Poultsides GA, Cho CS, Lopez-Aguiar AG, Kanji Z, Fisher AV, Krasnick BA, Idrees K, Makris E, Beems M, van Eijck CHJ, Nieveen van Dijkum EJM, Maithel SK, Pawlik TM (2021) Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers (Basel) 13:2242. https:\/\/doi.org\/10.3390\/cancers13092242","journal-title":"Cancers (Basel)"},{"key":"9933_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000518757","volume":"112","author":"CM Heidsma","year":"2022","unstructured":"Heidsma CM, van Roessel S, van Dieren S, Engelsman AF, Strobel O, Buechler MW, Schimmack S, Perinel J, Adham M, Deshpande V, Kjaer J, Norlen O, Gill AJ, Samra JS, Mittal A, Hoogwater FJH, Primavesi F, St\u00e4ttner S, Besselink MG, van Eijck CHJ, Nieveen van Dijkum EJM (2022) International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112:571\u2013579. https:\/\/doi.org\/10.1159\/000518757","journal-title":"Neuroendocrinology"},{"key":"9933_CR13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","volume":"23","author":"JY Kim","year":"2017","unstructured":"Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM (2017) Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res 23:1598\u20131606. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1147","journal-title":"Clin Cancer Res"},{"key":"9933_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","volume":"146","author":"I Marinoni","year":"2014","unstructured":"Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJM, Perren A (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146:453\u2013460.e5. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.020","journal-title":"Gastroenterology"},{"key":"9933_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, Bahary N, Brand RE, McGrath KM, Slivka A, Cressman KL, Fuhrer K, O\u2019Sullivan RJ (2017) Alternative Lengthening of Telomeres and Loss of DAXX\/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res 23:600\u2013609. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1113","journal-title":"Clin Cancer Res"},{"key":"9933_CR16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/SLA.0000000000003022","volume":"271","author":"A Pea","year":"2020","unstructured":"Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Chianchiano P, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL (2020) Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Ann Surg 271:566\u2013573. https:\/\/doi.org\/10.1097\/SLA.0000000000003022","journal-title":"Ann Surg"},{"key":"9933_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41525-018-0058-3","volume":"3","author":"B Lawrence","year":"2018","unstructured":"Lawrence B, Blenkiron C, Parker K, Tsai P, Fitzgerald S, Shields P, Robb T, Yeong ML, Kramer N, James S, Black M, Fan V, Poonawala N, Yap P, Coats E, Woodhouse B, Ramsaroop R, Yozu M, Robinson B, Henare K, Koea J, Johnston P, Carroll R, Connor S, Morrin H, Elston M, Jackson C, Reid P, Windsor J, MacCormick A, Babor R, Bartlett A, Damianovich D, Knowlton N, Grimmond S, Findlay M, Print C (2018) Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. NPJ Genom Med 3:18. https:\/\/doi.org\/10.1038\/s41525-018-0058-3","journal-title":"NPJ Genom Med"},{"key":"9933_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/PAS.0000000000001860","volume":"46","author":"M Parilla","year":"2022","unstructured":"Parilla M, Chapel D, Hechtman JF, Wanjari P, El Jabbour T, Sharma A, Ritterhouse L, Segal J, Vanderbilt C, Klimstra DS, Setia N, Tang L (2022) Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors. Am J Surg Pathol 46:823\u2013831. https:\/\/doi.org\/10.1097\/PAS.0000000000001860","journal-title":"Am J Surg Pathol"},{"key":"9933_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/PAS.0000000000002050","volume":"47","author":"AVD Verschuur","year":"2023","unstructured":"Verschuur AVD, Kok ASM, Morsink FHM, de Leng WWJ, van den Broek MFM, Koudijs MJ, Offerhaus JA, Valk GD, Vriens MR, van Nesselrooij BPM, Hackeng WM, Brosens LAA (2023) Diagnostic Utility of Menin Immunohistochemistry in Patients With Multiple Endocrine Neoplasia Type 1 Syndrome. Am J Surg Pathol 47:785\u2013791. https:\/\/doi.org\/10.1097\/PAS.0000000000002050","journal-title":"Am J Surg Pathol"},{"key":"9933_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425. https:\/\/doi.org\/10.1126\/science.1207313","journal-title":"Science"},{"key":"9933_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pan.2026.01.079","volume":"26","author":"GW Choi","year":"2026","unstructured":"Choi GW, Lee I, Seo Y, Han Y, Chae YS, Jung HS, Cho YJ, Kwon W, Jang JY, Park JS (2026) Prognostic and recurrence implications of subdividing WHO grade 2 pancreatic neuroendocrine tumors at a 10% Ki-67 threshold. Pancreatology 26:265\u2013271. https:\/\/doi.org\/10.1016\/j.pan.2026.01.079","journal-title":"Pancreatology"},{"key":"9933_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33:115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"9933_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12022-020-09611-8","volume":"31","author":"WM Hackeng","year":"2020","unstructured":"Hackeng WM, Schelhaas W, Morsink FHM, Heidsma CM, van Eeden S, Valk GD, Vriens MR, Heaphy CM, Nieveen van Dijkum EJM, Offerhaus GJA, Dreijerink KMA, Brosens LAA (2020) Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol 31:108\u2013118. https:\/\/doi.org\/10.1007\/s12022-020-09611-8","journal-title":"Endocr Pathol"},{"key":"9933_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80:27\u201338. https:\/\/doi.org\/10.1093\/biomet\/80.1.27","journal-title":"Biometrika"},{"key":"9933_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5603\/ep.98635","volume":"75","author":"H Olearska","year":"2024","unstructured":"Olearska H, Sowa-Staszczak A, Morawiec-S\u0142awek K, Kurzy\u0144ska A, Kolasa M, Tkacz E, Szumi\u0144ska M, Hubalewska-Dydejczyk A, Opalinska M (2024) Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection. Endokrynol Pol 75:102\u2013108. https:\/\/doi.org\/10.5603\/ep.98635","journal-title":"Endokrynol Pol"},{"key":"9933_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11912-021-01096-w","volume":"23","author":"C Luchini","year":"2021","unstructured":"Luchini C, Lawlor RT, Bersani S, Vicentini C, Paolino G, Mattiolo P, Pea A, Cingarlini S, Milella M, Scarpa A (2021) Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? Curr Oncol Rep 23:106. https:\/\/doi.org\/10.1007\/s11912-021-01096-w","journal-title":"Curr Oncol Rep"},{"key":"9933_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/gutjnl-2021-324664","volume":"71","author":"I Marinoni","year":"2022","unstructured":"Marinoni I (2022) Prognostic value of DAXX\/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation? Gut 71:847\u2013848. https:\/\/doi.org\/10.1136\/gutjnl-2021-324664","journal-title":"Gut"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-026-09933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-026-09933-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-026-09933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:41:20Z","timestamp":1787974880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-026-09933-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9933"],"URL":"https:\/\/doi.org\/10.1007\/s12022-026-09933-z","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Biobank Research Ethics Committees according to Dutch law and regulations (University Medical Center Utrecht Biobank Research Ethics Committee TcBio approval number #17\u2013881 and # 21\u2013507). Participants were informed about the potential use of their materials and data for research purposes and had the opportunity to object; individuals who objected were excluded from the study. Human Ethics and Consent to Participate declarations: not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"37"}}